CIK: 0001826434
Total reported value
$712.5M
Reporting period: 2026-03-31 · Number of holdings: 17
Tri Locum Partners LP disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $712.5M and a quarterly turnover rate of 80.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "T"
Tri Locum Partners LP's disclosed holdings carry a Herfindahl concentration index of 0.079 — mathematically equivalent to about 13 equally-sized positions, close to its 17 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.60), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 47% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim AXSM
-69.2% -$26.3M
Add DXCM
+65.6% $15.9M
Trim JNJ
-31.3% -$23.5M
Trim UTHR
-41.8% -$17.2M
Trim DNTH
-76.6% -$13.4M
Trim TEVA
-28.9% -$14.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | Stock-Healthcare | 14.22% | -1.99% | -31.28% | |
| 2 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 9.91% | +9.91% | NEW | |
| 3 | TMO | Thermo Fisher Scientific INC | Stock-Healthcare | 9.13% | +9.13% | NEW | |
| 4 | ASND | Ascendis Pharma A/S | Stock-Other | 8.20% | +0.86% | -3.65% | |
| 5 | VRTX | Vertex Pharmaceuticals INC | Stock-Healthcare | 8.10% | +8.10% | NEW | |
| 6 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.98% | -0.85% | -2.35% | |
| 7 | MDGL | Madrigal Pharmaceuticals INC | Stock-Healthcare | 7.59% | +1.09% | +20.07% | |
| 8 | DXCM | Dexcom INC | Stock-Healthcare | 6.15% | +2.52% | +65.60% | |
| 9 | UTHR | United Therapeutics CORP | Stock-Healthcare | 5.86% | -1.79% | -41.80% | |
| 10 | NUVL | Nuvalent Inc-a | Stock-Other | 4.44% | +0.43% | +0.37% | |
| 11 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.32% | -1.50% | -28.89% | |
| 12 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.21% | +4.21% | NEW | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.24% | -0.87% | -15.98% | |
| 14 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 2.49% | +2.49% | NEW | |
| 15 | DNTH | Dianthus Therapeutics INC | Stock-Other | 1.71% | -1.62% | -76.62% | |
| 16 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 1.47% | -3.31% | -69.19% | |
| 17 | DFTX | Definium Therapeutics INC | Stock-Other | 0.98% | +0.98% | NEW |
Performance for Q3 2026
+8.9%
Performance Last 4 Quarters
+65.9%
Based on 50% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 17 | $712.5M | 81 | |
| 2025-12-31 | 15 | $770.1M | 100 | |
| 2025-09-30 | 18 | $435.1M | 100 | |
| 2025-06-30 | 23 | $329.5M | 0 | |
| 2025-03-31 | 22 | $194.9M | 100 | |
| 2024-12-31 | 28 | $482.7M | 0 | |
| 2024-09-30 | 20 | $417.4M | 0 | |
| 2024-06-30 | 25 | $395.5M | 0 | |
| 2024-03-31 | 27 | $288.4M | 0 | |
| 2023-12-31 | 24 | $218.8M | 0 | |
| 2023-09-30 | 61 | $312.8M | 0 | |
| 2023-06-30 | 59 | $269.1M | 0 | |
| 2023-03-31 | 47 | $328.3M | 0 | |
| 2022-12-31 | 73 | $247.2M | 0 | |
| 2022-09-30 | 41 | $364.3M | 0 | |
| 2022-06-30 | 51 | $244.2M | 0 | |
| 2022-03-31 | 37 | $256.0M | 0 | |
| 2021-12-31 | 41 | $254.0M | 0 | |
| 2021-09-30 | 30 | $251.6M | 0 | |
| 2021-06-30 | 31 | $305.5M | 100 | |
| 2021-03-31 | 35 | $403.2M | 100 | |
| 2020-12-31 | 65 | $275.4M | 0 |
Tri Locum Partners LP's most significant position changes for 2026-03-31: Sold out: Danaher CORP (DHR); New buy: Intuitive Surgical INC (ISRG); New buy: Thermo Fisher Scientific INC (TMO); New buy: Vertex Pharmaceuticals INC (VRTX); Sold out: Boston Scientific CORP (BSX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DXCM | Dexcom INC | +2.5% | +65.60% | Add |
| 2 | MDGL | Madrigal Pharmaceuticals INC | +1.1% | +20.07% | Add |
| 3 | ASND | Ascendis Pharma A/S | +0.9% | -3.65% | Trim |
| 4 | NUVL | Nuvalent Inc-a | +0.4% | +0.37% | Add |
| 5 | LLY | Eli Lilly & Co | -0.9% | -2.35% | Trim |
| 6 | ARGX | Argenx Se - Adr | -0.9% | -15.98% | Trim |
| 7 | TEVA | Teva Pharmaceutical-sp Adr | -1.5% | -28.89% | Trim |
| 8 | DNTH | Dianthus Therapeutics INC | -1.6% | -76.62% | Trim |
| 9 | UTHR | United Therapeutics CORP | -1.8% | -41.80% | Trim |
| 10 | JNJ | Johnson & Johnson | -2% | -31.28% | Trim |
| 11 | AXSM | Axsome Therapeutics INC | -3.3% | -69.19% | Trim |
| 12 | DHR | Danaher CORP | — | EXIT | Sold out |
| 13 | ISRG | Intuitive Surgical INC | — | NEW | New buy |
| 14 | TMO | Thermo Fisher Scientific INC | — | NEW | New buy |
| 15 | VRTX | Vertex Pharmaceuticals INC | — | NEW | New buy |
| 16 | BSX | Boston Scientific CORP | — | EXIT | Sold out |
| 17 | IONS | Ionis Pharmaceuticals INC | — | EXIT | Sold out |
| 18 | VERA | Vera Therapeutics INC | — | EXIT | Sold out |
| 19 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 20 | TARS | Tarsus Pharmaceuticals INC | — | NEW | New buy |
| 21 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-18 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-14 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002088557
Total reported value
$712.2M
31 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0002109121
Total reported value
$712.2M
177 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001803291
Total reported value
$712.1M
110 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001300336
Total reported value
$2.6B
166 stks
2023-06-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Johnson & Johnson
CIK 0001381843
Total reported value
$309.7M
39 stks
2026-03-31
2 of the top 5 holdings overlap, including Thermo Fisher Scientific INC
CIK 0001694620
Total reported value
$8.3M
13 stks
2021-09-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Thermo Fisher Scientific INC